Your browser doesn't support javascript.
loading
Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer.
Huang, Monica L; Lane, Deanna L; Chang Sen, Lauren Q; Candelaria, Rosalind P; Kuerer, Henry M; Hunt, Kelly K; Akay, Catherine; Lim, Bora; Shaitelman, Simona; Hwang, Rosa F; Chen, Hui; Katta, Rajani; Santiago, Lumarie.
Affiliation
  • Huang ML; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1350, Houston, Texas 77030, USA (M.L.H., D.L.L., L.Q.C.S., R.P.C., L.S.). Electronic address: MLHuang@mdanderson.org.
  • Lane DL; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1350, Houston, Texas 77030, USA (M.L.H., D.L.L., L.Q.C.S., R.P.C., L.S.).
  • Chang Sen LQ; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1350, Houston, Texas 77030, USA (M.L.H., D.L.L., L.Q.C.S., R.P.C., L.S.).
  • Candelaria RP; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1350, Houston, Texas 77030, USA (M.L.H., D.L.L., L.Q.C.S., R.P.C., L.S.).
  • Kuerer HM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (H.M.K., K.K.H., C.A., R.F.H.).
  • Hunt KK; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (H.M.K., K.K.H., C.A., R.F.H.).
  • Akay C; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (H.M.K., K.K.H., C.A., R.F.H.).
  • Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (B.L.).
  • Shaitelman S; Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (S.S.).
  • Hwang RF; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA (H.M.K., K.K.H., C.A., R.F.H.).
  • Chen H; Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 0085, Houston, Texas 77030, USA (H.C.).
  • Katta R; McGovern Medical School at UTHealth Houston, 6750 West Loop South, #695, Bellaire, Texas 77401, USA (R.K.).
  • Santiago L; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1350, Houston, Texas 77030, USA (M.L.H., D.L.L., L.Q.C.S., R.P.C., L.S.).
Acad Radiol ; 2024 Aug 05.
Article in En | MEDLINE | ID: mdl-39107186
ABSTRACT
RATIONALE AND

OBJECTIVES:

Recent ICE3 trial of breast cryoablation for breast cancer demonstrated 98% success rate, similar to breast-conserving surgery. However, ICE3 and other published studies did not differentiate curative from palliative treatment nor define patient-specific treatment objectives. We sought to define treatment success of curative and palliative breast cryoablation for breast cancer in meeting procedure objectives and patient-specific treatment objectives. MATERIALS AND

METHODS:

We conducted a retrospective analysis of breast cancer patients who underwent breast cryoablation during 2021-2024. Breast radiologists performed outpatient cryoablation using local anesthesia and argon gas cryoprobes under ultrasound or MRI guidance. Patient demographics, referral indications, tumor characteristics, procedure details, and imaging follow-up findings were analyzed. Cryoablation was categorized as curative or palliative. Treatment success was defined as achievement of both procedure and patient-specific treatment objectives.

RESULTS:

Breast cryoablation was performed for 34 lesions in 29 patients with N0M0 (n = 25), N1M0 (n = 2), N2M0 (n = 1), and N0M1 (n = 1) disease. Most tumors were invasive ductal carcinoma (IDC), low to intermediate grade, estrogen receptor (ER) and progesterone receptor (PR) positive and HER2 negative (23 tumors, 68%). Tumor size ranged from 0.4-1.9 (median 0.8) cm for curative cryoablation and 0.6-6.0 (median 1.3) cm for palliative cryoablation. For 27 patients with follow-up imaging, ablation was curative in 14 patients, 14 tumors and palliative in 13 patients, 18 lesions. Imaging follow-up time ranged from 3 to 26 (median 16) months, > 12 months in 22 of 27 patients and 25 of 32 tumors. Complications were limited to 2 cases of skin frost injury, 1 mild and 1 moderate. Treatment success was achieved in 13 of 14 patients with curative and all 13 patients with palliative cryoablation.

CONCLUSION:

Our study defines treatment success for curative and palliative breast cryoablation, demonstrates breast cryoablation achieves not only procedure (technical) but also patient-specific treatment objectives without significant complications, and may serve as guide for integrating breast cryoablation in the treatment of breast cancer patients.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Acad Radiol Journal subject: RADIOLOGIA Year: 2024 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Acad Radiol Journal subject: RADIOLOGIA Year: 2024 Document type: Article Country of publication: United States